Drug
Shr-1258 dimaleate clinical trials
Also written Pyrotinib Maleate.
- studies test it
- 14
- open now
- 4
- in phase 3
- 1
- first study started
- 2018
Keep track of what changes. Save the shr-1258 dimaleate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
14 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 5 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 10
- Phase 3
- 1
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 12
Shengjing Hospital (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Hebei Medical University Fourth Hospital (2) · Caigang Liu (1) · Wuhan University (1) · Guangdong Association of Clinical Trials (1) · Zhongshan Hospital Xiamen University (1)
Often tested with
Tested in the same studies.
Letrozole (3) · Dalpiciclib (2) · Trastuzumab (2) · Albumin-Bound Paclitaxel (2) · Paclitaxel (2) · ARX788 (1) · Loperamide (1) · Vinorelbine (1)
Studies
Open first, then newest update. How each study uses shr-1258 dimaleate is read from its arms, and is right about nine times in ten.
Testing it · 14
- Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast CancerRecruitingPhase 2Hebei Medical University Fourth HospitalNCT07635342Written as Pyrotinib Maleate
- Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI TherapyNot yet recruitingNot applicableTianjin Medical University Cancer Institute and HospitalNCT05560308Written as Pyrotinib Maleate Tablets
- Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBCRecruitingPhase 2Shengjing HospitalNCT05228951Written as Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole
- Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HPNot yet recruitingPhase 4Wuhan UniversityNCT04929548Written as Pyrotinib Maleate Tablets
- A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer PatientsActive, not recruitingPhase 2/3Caigang LiuNCT05426486Written as Pyrotinib maleate
- Phase II Umbrella Study Directed by Next Generation SequencingStatus unknownPhase 2Guangdong Association of Clinical TrialsNCT03574402Written as Pyrotinib Maleate
- A Drug-drug Interaction Trial of Loperamide Pharmacokinetics Effect on Pyrotinib MaleateCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04315116Written as pyrotinib maleate
- Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II TrialActive, not recruitingPhase 2Shengjing HospitalNCT04486911Written as Pyrotinib maleate, SHR6390, letrozole
- Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast CancerCompletedPhase 2Tianjin Medical University Cancer Institute and HospitalNCT04903652Written as Pyrotinib Maleate
- An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid TumorsStatus unknownPhase 2Zhongshan Hospital Xiamen UniversityNCT05274191Written as Pyrotinib Maleate
- Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast CancerStatus unknownPhase 2Hunan Cancer HospitalNCT04407988Written as Pyrotinib Maleate plus Letrozole
- Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A InducerStatus unknownPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04680091Written as Pyrotinib Maleate
- Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast CancerStatus unknownPhase 1/2West China HospitalNCT04152057Written as Pyrotinib Maleate Tablets
- Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory StudyStatus unknownPhase 2Hebei Medical University Fourth HospitalNCT03919253Written as pyrotinib maleate tablets+nab-paclitaxel
Given in every arm · 2 — shr-1258 dimaleate is usual care beside what is tested
- A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid TumorsRecruitingPhase 1/2Risen (Suzhou) Pharma Tech Co., Ltd.NCT06208410Written as Pyrotinib Maleate Tablets
- Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)Active, not recruitingPhase 2Henan Cancer HospitalNCT05328440Written as Pyrotinib Maleate
Codes
What other systems call shr-1258 dimaleate · ClinicalTrials.gg INT015600
- UNII (FDA) 85KUE857XMPYROTINIB MALEATEConfirmed FDA, Wikidata
- Wikidata Q27269653shr-1258 dimaleateConfirmed FDA, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 85KUE857XM | PYROTINIB MALEATE | Confirmed FDA, Wikidata |
| Wikidata | Q27269653 | shr-1258 dimaleate | Confirmed FDA, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.